ClinicalTrials.gg
Active, not recruitingNCT04909801Updated Feb 19, 2025Results posted

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

A Phase 3 interventional study of Abatacept and Adalimumab in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Active, not recruiting at 75 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
338
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
18th of 63
338 · median 119
Started
2021
with 1 other
Phase 3
26 of 63
2 open now
Registered
58th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 18th largest by enrollment, is one of 2 that started in 2021, is one of 26 in phase 3, and was the 58th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the superiority in efficacy of abatacept compared with adalimumab, on background methotrexate, in adults with early, seropositive, and shared epitope-positive rheumatoid arthritis and an inadequate methotrexate response.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Abatacept
  • Adalimumab
  • BMS-188667
  • Humira®
  • Methotrexate
  • Orencia®
  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Early rheumatoid arthritis (RA), defined as symptoms of RA that started ≤ 12 months prior to screening and satisfied the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria for the classification of RA at some point during the 12-month period
  • Naïve to any targeted (biologic or nonbiologic) disease-modifying antirheumatic drugs (DMARDs), conventional synthetic DMARDs other than methotrexate (MTX), or therapies for RA
  • Treated with MTX for at least 12 weeks, with a stable dose of oral or parenteral MTX for at least 4 weeks prior to randomization
  • Anti-cyclic citrullinated peptide-2 (Anti-CCP-2) test that is > 3× the and are positive for rheumatoid factor (RF) according to central lab testing during screening
  • At least a Disease Activity Score 28-joint count calculated using C-reactive protein (DAS28-CRP) ≥ 3.2 at screening
  • At least 3 tender and at least 3 swollen joints at screening and at randomization

Exclusion criteria

Exclusion Criteria:

  • Women who are breastfeeding
  • disease other than RA (e.g., psoriasis, systemic lupus erythematosus [SLE], vasculitis, seronegative spondyloarthritis, inflammatory bowel disease, Sjogren's syndrome) or currently active fibromyalgia
  • History of or current inflammatory joint disease other than RA (e.g., psoriatic arthritis, gout, reactive arthritis, Lyme disease)
  • At risk for tuberculosis
  • Recent acute infection
  • History of chronic or recurrent bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, bronchiectasis)
  • History of infection of a joint prosthesis or artificial joint
  • History of systemic fungal infections (such as histoplasmosis, blastomycosis, or coccidiomycosis)
  • History of primary immunodeficiency
  • Current clinical findings or a history of a demyelinating disorder
  • 5 or more joints cannot be assessed for tenderness or swelling

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
338 participants (actual)

Study arms

  • Experimental
    Arm 1: Abatacept + Methotrexate

    Drug: Abatacept · Drug: Methotrexate

  • Experimental
    Arm 2: (Adalimumab + Methotrexate) followed by (Abatacept + Methotrexate)

    Drug: Abatacept · Drug: Adalimumab · Drug: Methotrexate

Interventions

  • Abatacept SC (125 mg) once weekly

    Also known as: BMS-188667, Orencia®

  • Adalimumab SC (40 mg) once every 2 weeks

    Also known as: Humira®

  • Methotrexate oral/parenteral maximum tolerated dose (minimum 15 mg and maximum 25 mg weekly)

06

What researchers measure

Primary outcomes

  1. Percentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24

    The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

    Time frame: Baseline, week 24

Secondary outcomes

  1. Percentage of SE+ Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) at Week 24

    DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS.

    Time frame: Week 24

  2. Percentage of Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24

    The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

    Time frame: Baseline, week 24

  3. Percentage of SE+ Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) at Week 24

    CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm.

    Time frame: Week 24

  4. Adjusted Mean Change From Baseline in SE+ Participant-Reported Pain Visual Analog Scale (VAS) at Week 24

    Participant-reported pain by a 0-100mm visual analog scale; higher score indicates more pain. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Baseline, week 24

  5. Percentage of SE+ Participants Meeting 20% Improvement in American College of Rheumatology Criteria (ACR20) Response Over Time

    The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  6. Percentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response Over Time

    The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  7. Percentage of SE+ Participants Meeting 70% Improvement in American College of Rheumatology Criteria (ACR70) Response Over Time

    The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  8. Percentage of SE+ Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) Over Time

    DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS.

    Time frame: Day 29, 57, 85, 113, 141, 169

  9. Percentage of SE+ Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) Over Time

    CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm.

    Time frame: Day 29, 57, 85, 113, 141, 169

  10. Percentage of SE+ Participants Achieving Simple Disease Activity Index Remission (SDAI <= 3.3) Over Time

    SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL.

    Time frame: Day 29, 57, 85, 113, 141, 169

  11. Percentage of Participants Meeting 20% Improvement in American College of Rheumatology Criteria (ACR20) Response Over Time

    The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  12. Percentage of Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response Over Time

    The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  13. Percentage of Participants Meeting 70% Improvement in American College of Rheumatology Criteria (ACR70) Response Over Time

    The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  14. Percentage of Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) Over Time

    DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS.

    Time frame: Day 29, 57, 85, 113, 141, 169

  15. Percentage of Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) Over Time

    CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm.

    Time frame: Day 29, 57, 85, 113, 141, 169

  16. Percentage of Participants Achieving Simple Disease Activity Index Remission (SDAI <= 3.3) Over Time

    SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL.

    Time frame: Day 29, 57, 85, 113, 141, 169

  17. Adjusted Mean Change From Baseline in Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein (DAS28-CRP) Over Time for SE+ Participants

    DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. Remission was defined as DAS28-CRP \< 2.6. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  18. Adjusted Mean Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time for SE+ Participants

    CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI remission was defined as =\<2.8. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  19. Adjusted Mean Change From Baseline in Simple Disease Activity Index (SDAI) Over Time for SE+ Participants

    SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. Remission was defined as SDAI =\< 3.3. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  20. Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 3-5 Over Time for SE+ Participants

    1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  21. Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 1-2 Over Time for SE+ Participants

    1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  22. Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 6 Over Time for SE+ Participants

    6) Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI). For the eight disability categories (Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities), there is an aids or devices variables to record the type of assistance. If aids or devices and/or assistance from another person are checked for a category, the score is set to 2 (much difficulty), if the original score is 0 (no difficulty) or 1 (some difficulty). HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered (increasing scores for the 8 disability categories questionnaire indicate increasing level of difficulty with 0 being the lowest score "without any difficulty" and 3 being the highest score "unable to do". Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  23. Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 7 Over Time for SE+ Participants

    1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  24. Adjusted Mean Change From Baseline in Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein (DAS28-CRP) Over Time for All Participants

    DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. Remission was defined as DAS28-CRP \< 2.6. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  25. Adjusted Mean Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time for All Participants

    CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI remission was defined as =\<2.8. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  26. Adjusted Mean Change From Baseline in Simple Disease Activity Index (SDAI) Over Time for All Participants

    SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. Remission was defined as SDAI =\< 3.3. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  27. Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 3-5 Over Time for All Participants

    1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  28. Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 1-2 Over Time for All Participants

    1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  29. Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 6 Over Time for All Participants

    6) Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI). For the eight disability categories (Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities), there is an aids or devices variables to record the type of assistance. If aids or devices and/or assistance from another person are checked for a category, the score is set to 2 (much difficulty), if the original score is 0 (no difficulty) or 1 (some difficulty). HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered (increasing scores for the 8 disability categories questionnaire indicate increasing level of difficulty with 0 being the lowest score "without any difficulty" and 3 being the highest score "unable to do". Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  30. Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 7 Over Time for All Participants

    1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

    Time frame: Baseline, day 29, 57, 85, 113, 141, 169

  31. Adjusted Mean Change From Baseline in 36-item Short Form Survey (SF-36) Over Time for SE+ Participants

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life, which covers 8 health dimensions within 2 components. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100, with a higher score indicating better quality of life. The 8 subscales will be scored using norm-based methods that have standardized the T-scores to a mean of 50 and a standard deviation of 10 in the general population.

    Time frame: Up to week 24

  32. Adjusted Mean Change From Baseline in SF-36 Over Time for All Participants

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life, which covers 8 health dimensions within 2 components. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100, with a higher score indicating better quality of life. The 8 subscales will be scored using norm-based methods that have standardized the T-scores to a mean of 50 and a standard deviation of 10 in the general population.

    Time frame: Up to week 24

  33. Adjusted Mean Change From Baseline in 36-item Short Form Survey (SF-36) at Week 104 for SE+ Participants

    The SF-36 v2.0, which covers 8 health dimensions within 2 components. The physical component summary (PCS) of the SF-36 consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. The 2 summary scores (PCS and MCS) will be calculated by taking a weighted linear combination of the 8 individual subscales. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Up to week 24

  34. Adjusted Mean Change From Baseline in 36-item Short Form Survey (SF-36) at Week 104 for All Participants

    The SF-36 v2.0, which covers 8 health dimensions within 2 components. The physical component summary (PCS) of the SF-36 consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. The 2 summary scores (PCS and MCS) will be calculated by taking a weighted linear combination of the 8 individual subscales. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

    Time frame: Up to week 24

07

Results

Posted Oct 15, 2024

Participant flow

Participant flow — Overall Study
MilestoneAbataceptAdalimumab, Then Abatacept (OLE Period)
Started169169
Treated in open-label160161
Completed162162
Not completed77
Withdrew: Lack of efficacy21
Withdrew: Adverse event12
Withdrew: Participant request to discontinue study treatment12
Withdrew: Withdrawal by subject21
Withdrew: Other reasons11

Outcome measures

PrimaryPercentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24

The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

Time frame:
Baseline, week 24
Reported as:
Number · Percentage of participants
Percentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Percentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 2459.0 (49.5 to 68.0)60.3 (50.8 to 69.3)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.9026 · Adjusted odds ratio: 1.0 · 95% CI 0.6 to 1.6
SecondaryPercentage of SE+ Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) at Week 24

DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of SE+ Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) at Week 24
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Percentage of SE+ Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) at Week 2444.4 (35.3 to 53.9)46.6 (37.2 to 56.0)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.5824 · Adjusted odds ratio: 0.9 · 95% CI 0.5 to 1.5
SecondaryPercentage of Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24

The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

Time frame:
Baseline, week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Percentage of Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 2459.2 (51.4 to 66.7)63.9 (56.2 to 71.1)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.3534 · Adjusted odds ratio: 0.8 · 95% CI 0.5 to 1.3
SecondaryPercentage of SE+ Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) at Week 24

CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of SE+ Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) at Week 24
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Percentage of SE+ Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) at Week 2433.3 (24.9 to 42.6)35.3 (26.7 to 44.8)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.6140 · Adjusted odds ratio: 0.9 · 95% CI 0.5 to 1.5
SecondaryAdjusted Mean Change From Baseline in SE+ Participant-Reported Pain Visual Analog Scale (VAS) at Week 24

Participant-reported pain by a 0-100mm visual analog scale; higher score indicates more pain. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Baseline, week 24
Reported as:
Mean · Score on a scale
Adjusted Mean Change From Baseline in SE+ Participant-Reported Pain Visual Analog Scale (VAS) at Week 24
Score on a scaleAbataceptAdalimumab, Then Abatacept (OLE Period)
Adjusted Mean Change From Baseline in SE+ Participant-Reported Pain Visual Analog Scale (VAS) at Week 24-40.9 ± 2.256-37.7 ± 2.288
SecondaryPercentage of SE+ Participants Meeting 20% Improvement in American College of Rheumatology Criteria (ACR20) Response Over Time

The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Number · Percentage of participants
Percentage of SE+ Participants Meeting 20% Improvement in American College of Rheumatology Criteria (ACR20) Response Over Time
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 2947.0 (37.7 to 56.5)51.7 (42.3 to 61.1)
Day 5766.7 (57.4 to 75.1)71.6 (62.4 to 79.5)
Day 8574.4 (65.5 to 82.0)75.9 (67.0 to 83.3)
Day 11385.5 (77.8 to 91.3)76.7 (68.0 to 84.1)
Day 14182.9 (74.8 to 89.2)79.3 (70.8 to 86.3)
Day 16976.9 (68.2 to 84.2)75.9 (67.0 to 83.3)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.4996 · Adjusted odds ratio: 0.8 · 95% CI 0.5 to 1.4
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.4490 · Adjusted odds ratio: 0.8 · 95% CI 0.5 to 1.4
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.8090 · Adjusted odds ratio: 0.9 · 95% CI 0.5 to 1.7
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.0739 · Adjusted odds ratio: 1.9 · 95% CI 0.9 to 3.6
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.4201 · Adjusted odds ratio: 1.3 · 95% CI 0.7 to 2.6
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.7928 · Adjusted odds ratio: 1.1 · 95% CI 0.6 to 2.0
SecondaryPercentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response Over Time

The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Number · Percentage of participants
Percentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response Over Time
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 2920.5 (13.6 to 29.0)26.7 (18.9 to 35.7)
Day 5738.5 (29.6 to 47.9)43.1 (33.9 to 52.6)
Day 8554.7 (45.2 to 63.9)54.3 (44.8 to 63.6)
Day 11360.7 (51.2 to 69.6)59.5 (50.0 to 68.5)
Day 14160.7 (51.2 to 69.6)60.3 (50.8 to 69.3)
Day 16959.0 (49.5 to 68.0)60.3 (50.8 to 69.3)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.2701 · Adjusted odds ratio: 0.7 · 95% CI 0.4 to 1.3
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.4863 · Adjusted odds ratio: 0.8 · 95% CI 0.5 to 1.4
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.9513 · Adjusted odds ratio: 1.0 · 95% CI 0.6 to 1.7
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.8536 · Adjusted odds ratio: 1.1 · 95% CI 0.6 to 1.8
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.9223 · Adjusted odds ratio: 1.0 · 95% CI 0.6 to 1.7
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.9026 · Adjusted odds ratio: 1.0 · 95% CI 0.6 to 1.6
SecondaryPercentage of SE+ Participants Meeting 70% Improvement in American College of Rheumatology Criteria (ACR70) Response Over Time

The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Number · Percentage of participants
Percentage of SE+ Participants Meeting 70% Improvement in American College of Rheumatology Criteria (ACR70) Response Over Time
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 296.8 (3.0 to 13.0)10.3 (5.5 to 17.4)
Day 5717.9 (11.5 to 26.1)24.1 (16.7 to 33.0)
Day 8530.8 (22.6 to 40.0)35.3 (26.7 to 44.8)
Day 11335.0 (26.5 to 44.4)35.3 (26.7 to 44.8)
Day 14140.2 (31.2 to 49.6)44.0 (34.8 to 53.5)
Day 16939.3 (30.4 to 48.8)47.4 (38.1 to 56.9)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.3411 · Adjusted odds ratio: 0.6 · 95% CI 0.2 to 1.6
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.2546 · Adjusted odds ratio: 0.7 · 95% CI 0.4 to 1.3
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.4558 · Adjusted odds ratio: 0.8 · 95% CI 0.5 to 1.4
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.9544 · Adjusted odds ratio: 1.0 · 95% CI 0.6 to 1.7
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.5450 · Adjusted odds ratio: 0.9 · 95% CI 0.5 to 1.4
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.2227 · Adjusted odds ratio: 0.7 · 95% CI 0.4 to 1.2
SecondaryPercentage of SE+ Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) Over Time

DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS.

Time frame:
Day 29, 57, 85, 113, 141, 169
Reported as:
Number · Percentage of participants
Percentage of SE+ Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) Over Time
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 2912.8 (7.4 to 20.3)16.4 (10.2 to 24.4)
Day 5730.8 (22.6 to 40.0)32.8 (24.3 to 42.1)
Day 8541.0 (32.0 to 50.5)40.5 (31.5 to 50.0)
Day 11349.6 (40.2 to 59.0)52.6 (43.1 to 61.9)
Day 14154.7 (45.2 to 63.9)52.6 (43.1 to 61.9)
Day 16944.4 (35.3 to 53.9)46.6 (37.2 to 56.0)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.3200 · Adjusted odds ratio: 0.7 · 95% CI 0.3 to 1.4
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.4992 · Adjusted odds ratio: 0.8 · 95% CI 0.5 to 1.5
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.8963 · Adjusted odds ratio: 1.0 · 95% CI 0.6 to 1.7
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.4544 · Adjusted odds ratio: 0.8 · 95% CI 0.5 to 1.4
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.8985 · Adjusted odds ratio: 1.0 · 95% CI 0.6 to 1.8
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.5824 · Adjusted odds ratio: 0.9 · 95% CI 0.5 to 1.5
SecondaryPercentage of SE+ Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) Over Time

CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm.

Time frame:
Day 29, 57, 85, 113, 141, 169
Reported as:
Number · Percentage of participants
Percentage of SE+ Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) Over Time
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 299.4 (4.8 to 16.2)6.0 (2.5 to 12.0)
Day 5717.1 (10.8 to 25.2)13.8 (8.1 to 21.4)
Day 8526.5 (18.8 to 35.5)19.8 (13.0 to 28.3)
Day 11329.1 (21.0 to 38.2)32.8 (24.3 to 42.1)
Day 14134.2 (25.7 to 43.5)30.2 (22.0 to 39.4)
Day 16933.3 (24.9 to 42.6)35.3 (26.7 to 44.8)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.4152 · Adjusted odds ratio: 1.5 · 95% CI 0.6 to 4.1
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.5917 · Adjusted odds ratio: 1.2 · 95% CI 0.6 to 2.5
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.3348 · Adjusted odds ratio: 1.4 · 95% CI 0.7 to 2.6
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.3959 · Adjusted odds ratio: 0.8 · 95% CI 0.4 to 1.4
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.6225 · Adjusted odds ratio: 1.2 · 95% CI 0.7 to 2.0
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.6140 · Adjusted odds ratio: 0.9 · 95% CI 0.5 to 1.5
SecondaryPercentage of SE+ Participants Achieving Simple Disease Activity Index Remission (SDAI <= 3.3) Over Time

SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL.

Time frame:
Day 29, 57, 85, 113, 141, 169
Reported as:
Number · Percentage of participants
Percentage of SE+ Participants Achieving Simple Disease Activity Index Remission (SDAI <= 3.3) Over Time
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 299.4 (4.8 to 16.2)7.8 (3.6 to 14.2)
Day 5717.1 (10.8 to 25.2)14.7 (8.8 to 22.4)
Day 8524.8 (17.3 to 33.6)19.8 (13.0 to 28.3)
Day 11331.6 (23.3 to 40.9)31.9 (23.6 to 41.2)
Day 14135.9 (27.2 to 45.3)32.8 (24.3 to 42.1)
Day 16933.3 (24.9 to 42.6)34.5 (25.9 to 43.9)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.8084 · Adjusted odds ratio: 1.1 · 95% CI 0.4 to 2.9
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.7470 · Adjusted odds ratio: 1.1 · 95% CI 0.5 to 2.3
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.5233 · Adjusted odds ratio: 1.2 · 95% CI 0.7 to 2.3
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.7295 · Adjusted odds ratio: 0.9 · 95% CI 0.5 to 1.6
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.7621 · Adjusted odds ratio: 1.1 · 95% CI 0.6 to 1.9
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.6861 · Adjusted odds ratio: 0.9 · 95% CI 0.5 to 1.6
SecondaryPercentage of Participants Meeting 20% Improvement in American College of Rheumatology Criteria (ACR20) Response Over Time

The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting 20% Improvement in American College of Rheumatology Criteria (ACR20) Response Over Time
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 2946.7 (39.0 to 54.6)52.1 (44.3 to 59.8)
Day 5766.3 (58.6 to 73.4)68.6 (61.1 to 75.5)
Day 8572.8 (65.4 to 79.3)76.3 (69.2 to 82.5)
Day 11385.2 (78.9 to 90.2)79.9 (73.0 to 85.6)
Day 14184.0 (77.6 to 89.2)79.9 (73.0 to 85.6)
Day 16977.5 (70.5 to 83.6)76.9 (69.8 to 83.0)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.3117 · Adjusted odds ratio: 0.8 · 95% CI 0.5 to 1.2
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.6120 · Adjusted odds ratio: 0.9 · 95% CI 0.6 to 1.4
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.4339 · Adjusted odds ratio: 0.8 · 95% CI 0.5 to 1.3
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.1963 · Adjusted odds ratio: 1.5 · 95% CI 0.8 to 2.6
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.3275 · Adjusted odds ratio: 1.3 · 95% CI 0.8 to 2.3
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.9113 · Adjusted odds ratio: 1.0 · 95% CI 0.6 to 1.7
SecondaryPercentage of Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response Over Time

The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response Over Time
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 2920.1 (14.4 to 27.0)27.2 (20.7 to 34.6)
Day 5738.5 (31.1 to 46.2)41.4 (33.9 to 49.2)
Day 8552.7 (44.9 to 60.4)53.3 (45.4 to 61.0)
Day 11360.4 (52.6 to 67.8)59.8 (52.0 to 67.2)
Day 14161.5 (53.8 to 68.9)58.6 (50.8 to 66.1)
Day 16959.2 (51.4 to 66.7)63.9 (56.2 to 71.1)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.1247 · Adjusted odds ratio: 0.7 · 95% CI 0.4 to 1.1
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.5656 · Adjusted odds ratio: 0.9 · 95% CI 0.6 to 1.4
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.8970 · Adjusted odds ratio: 1.0 · 95% CI 0.6 to 1.5
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.9175 · Adjusted odds ratio: 1.0 · 95% CI 0.7 to 1.6
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.5996 · Adjusted odds ratio: 1.1 · 95% CI 0.7 to 1.7
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.3534 · Adjusted odds ratio: 0.8 · 95% CI 0.5 to 1.3
SecondaryPercentage of Participants Meeting 70% Improvement in American College of Rheumatology Criteria (ACR70) Response Over Time

The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting 70% Improvement in American College of Rheumatology Criteria (ACR70) Response Over Time
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 295.9 (2.9 to 10.6)10.1 (6.0 to 15.6)
Day 5720.7 (14.9 to 27.6)23.1 (17.0 to 30.2)
Day 8530.2 (23.4 to 37.7)32.0 (25.0 to 39.6)
Day 11335.5 (28.3 to 43.2)33.7 (26.6 to 41.4)
Day 14140.2 (32.8 to 48.0)40.8 (33.3 to 48.6)
Day 16939.1 (31.7 to 46.8)45.0 (37.3 to 52.8)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.1641 · Adjusted odds ratio: 0.6 · 95% CI 0.2 to 1.3
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.5905 · Adjusted odds ratio: 0.9 · 95% CI 0.5 to 1.5
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.7146 · Adjusted odds ratio: 0.9 · 95% CI 0.6 to 1.5
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.7416 · Adjusted odds ratio: 1.1 · 95% CI 0.7 to 1.7
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.9026 · Adjusted odds ratio: 1.0 · 95% CI 0.6 to 1.5
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.2605 · Adjusted odds ratio: 0.8 · 95% CI 0.5 to 1.2
SecondaryPercentage of Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) Over Time

DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS.

Time frame:
Day 29, 57, 85, 113, 141, 169
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) Over Time
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 2910.7 (6.4 to 16.3)16.6 (11.3 to 23.0)
Day 5727.2 (20.7 to 34.6)33.7 (26.6 to 41.4)
Day 8537.3 (30.0 to 45.0)40.8 (33.3 to 48.6)
Day 11349.7 (41.9 to 57.5)54.4 (46.6 to 62.1)
Day 14154.4 (46.6 to 62.1)51.5 (43.7 to 59.2)
Day 16946.7 (39.0 to 54.6)50.9 (43.1 to 58.6)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.1078 · Adjusted odds ratio: 0.6 · 95% CI 0.3 to 1.1
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.1855 · Adjusted odds ratio: 0.7 · 95% CI 0.4 to 1.2
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.5223 · Adjusted odds ratio: 0.9 · 95% CI 0.6 to 1.4
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.4078 · Adjusted odds ratio: 0.8 · 95% CI 0.5 to 1.3
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.5238 · Adjusted odds ratio: 1.2 · 95% CI 0.7 to 1.8
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.4740 · Adjusted odds ratio: 0.9 · 95% CI 0.5 to 1.3
SecondaryPercentage of Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) Over Time

CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm.

Time frame:
Day 29, 57, 85, 113, 141, 169
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) Over Time
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 297.7 (4.2 to 12.8)6.5 (3.3 to 11.3)
Day 5715.4 (10.3 to 21.7)14.2 (9.3 to 20.4)
Day 8524.9 (18.5 to 32.1)20.7 (14.9 to 27.6)
Day 11331.4 (24.5 to 38.9)29.0 (22.3 to 36.5)
Day 14134.3 (27.2 to 42.0)29.0 (22.3 to 36.5)
Day 16933.7 (26.6 to 41.4)32.5 (25.5 to 40.2)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.6565 · Adjusted odds ratio: 1.2 · 95% CI 0.5 to 2.9
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.7010 · Adjusted odds ratio: 1.1 · 95% CI 0.6 to 2.1
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.3683 · Adjusted odds ratio: 1.3 · 95% CI 0.8 to 2.1
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.6372 · Adjusted odds ratio: 1.1 · 95% CI 0.7 to 1.8
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.2922 · Adjusted odds ratio: 1.3 · 95% CI 0.8 to 2.0
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.8178 · Adjusted odds ratio: 1.1 · 95% CI 0.7 to 1.7
SecondaryPercentage of Participants Achieving Simple Disease Activity Index Remission (SDAI <= 3.3) Over Time

SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL.

Time frame:
Day 29, 57, 85, 113, 141, 169
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Simple Disease Activity Index Remission (SDAI <= 3.3) Over Time
Percentage of participantsAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 297.7 (4.2 to 12.8)7.7 (4.2 to 12.8)
Day 5714.8 (9.8 to 21.1)16.0 (10.8 to 22.4)
Day 8523.1 (17.0 to 30.2)20.7 (14.9 to 27.6)
Day 11333.1 (26.1 to 40.8)28.4 (21.7 to 35.8)
Day 14135.5 (28.3 to 43.2)28.4 (21.7 to 35.8)
Day 16934.3 (27.2 to 42.0)31.4 (24.5 to 38.9)
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.9599 · Adjusted odds ratio: 1.0 · 95% CI 0.4 to 2.2
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.7899 · Adjusted odds ratio: 0.9 · 95% CI 0.5 to 1.7
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.6305 · Adjusted odds ratio: 1.1 · 95% CI 0.7 to 1.9
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.3491 · Adjusted odds ratio: 1.3 · 95% CI 0.8 to 2.0
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.4916 · Adjusted odds ratio: 1.2 · 95% CI 0.7 to 1.9
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · Regression, Logistic · p = 0.5697 · Adjusted odds ratio: 1.1 · 95% CI 0.7 to 1.8
SecondaryAdjusted Mean Change From Baseline in Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein (DAS28-CRP) Over Time for SE+ Participants

DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. Remission was defined as DAS28-CRP \< 2.6. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Mean · score on a scale
Adjusted Mean Change From Baseline in Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein (DAS28-CRP) Over Time for SE+ Participants
score on a scaleAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 29-1.3 ± 0.099-1.6 ± 0.099
Day 57-2.0 ± 0.104-2.1 ± 0.109
Day 85-2.3 ± 0.109-2.4 ± 0.112
Day 113-2.7 ± 0.099-2.6 ± 0.101
Day 141-2.7 ± 0.101-2.6 ± 0.102
Day 169-2.6 ± 0.114-2.6 ± 0.116
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.0977 · Adjusted mean difference: 0.2 · 95% CI -0.0 to 0.5
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.2889 · Adjusted mean difference: 0.2 · 95% CI -0.1 to 0.5
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.7676 · Adjusted mean difference: 0.0 · 95% CI -0.3 to 0.4
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.6157 · Adjusted mean difference: -0.1 · 95% CI -0.3 to 0.2
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.3904 · Adjusted mean difference: -0.1 · 95% CI -0.4 to 0.2
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.8359 · Adjusted mean difference: -0.0 · 95% CI -0.4 to 0.3
SecondaryAdjusted Mean Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time for SE+ Participants

CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI remission was defined as =\<2.8. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Mean · score on a scale
Adjusted Mean Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time for SE+ Participants
score on a scaleAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 29-15.5 ± 0.972-15.9 ± 0.955
Day 57-21.3 ± 0.928-21.9 ± 0.949
Day 85-24.6 ± 0.928-23.7 ± 0.945
Day 113-26.8 ± 0.798-25.6 ± 0.808
Day 141-27.3 ± 0.783-25.6 ± 0.780
Day 169-26.9 ± 0.959-25.5 ± 0.959
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.7852 · Adjusted mean difference: 0.4 · 95% CI -2.3 to 3.1
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.6336 · Adjusted mean difference: 0.6 · 95% CI -2.0 to 3.3
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.4879 · Adjusted mean difference: -0.9 · 95% CI -3.5 to 1.7
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.2812 · Adjusted mean difference: -1.2 · 95% CI -3.5 to 1.0
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.1205 · Adjusted mean difference: -1.7 · 95% CI -3.9 to 0.5
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.3001 · Adjusted mean difference: -1.4 · 95% CI -4.1 to 1.3
SecondaryAdjusted Mean Change From Baseline in Simple Disease Activity Index (SDAI) Over Time for SE+ Participants

SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. Remission was defined as SDAI =\< 3.3. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Mean · score on a scale
Adjusted Mean Change From Baseline in Simple Disease Activity Index (SDAI) Over Time for SE+ Participants
score on a scaleAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 29-15.6 ± 1.008-16.7 ± 0.990
Day 57-21.9 ± 0.931-22.5 ± 0.962
Day 85-25.3 ± 0.935-24.6 ± 0.953
Day 113-27.5 ± 0.797-26.3 ± 0.807
Day 141-28.1 ± 0.791-26.4 ± 0.787
Day 169-27.6 ± 0.978-26.1 ± 0.983
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.4107 · Adjusted mean difference: 1.2 · 95% CI -1.6 to 4.0
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.6824 · Adjusted mean difference: 0.5 · 95% CI -2.1 to 3.2
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.5793 · Adjusted mean difference: -0.7 · 95% CI -3.4 to 1.9
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.2883 · Adjusted mean difference: -1.5 · 95% CI -4.2 to 1.2
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.1285 · Adjusted mean difference: -1.7 · 95% CI -3.9 to 0.5
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.2815 · Adjusted mean difference: -1.5 · 95% CI -4.2 to 1.2
SecondaryAdjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 3-5 Over Time for SE+ Participants

1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Mean · score on a scale
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 3-5 Over Time for SE+ Participants
score on a scaleAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 29: Participants Global Assess Disease Activity (mm)-20.0 ± 2.230-21.4 ± 2.230
Day 29: Physician Global Assess Disease Activity (mm)-26.8 ± 1.896-27.1 ± 1.870
Day 29: Participants Assessment of Pain (mm)-19.5 ± 2.219-23.6 ± 2.229
Day 57: Participants Global Assess Disease Activity (mm)-25.7 ± 2.205-28.4 ± 2.276
Day 57: Physician Global Assess Disease Activity (mm)-37.7 ± 1.782-37.6 ± 1.806
Day 57: Participants Assessment of Pain (mm)-24.8 ± 2.305-29.1 ± 2.358
Day 85: Participants Global Assess Disease Activity (mm)-33.4 ± 2.239-32.9 ± 2.302
Day 85: Physician Global Assess Disease Activity (mm)-43.8 ± 1.660-42.2 ± 1.675
Day 85: Participants Assessment of Pain (mm)-33.1 ± 2.321-33.3 ± 2.363
Day 113: Participants Global Assess Disease Activity (mm)-37.7 ± 2.124-35.7 ± 2.162
Day 113: Physician Global Assess Disease Activity (mm)-47.6 ± 1.462-45.8 ± 1.482
Day 113: Participants Assessment of Pain (mm)-37.0 ± 2.207-34.3 ± 2.237
Day 141: Participants Global Assess Disease Activity (mm)-38.8 ± 2.243-35.0 ± 2.274
Day 141: Physician Global Assess Disease Activity (mm)-48.9 ± 1.498-45.7 ± 1.491
Day 141: Participants Assessment of Pain (mm)-39.0 ± 2.212-38.3 ± 2.223
Day 169: Participants Global Assess Disease Activity (mm)-39.6 ± 2.237-36.0 ± 2.278
Day 169: Physician Global Assess Disease Activity (mm)-48.0 ± 1.683-45.9 ± 1.683
Day 169: Participants Assessment of Pain (mm)-40.9 ± 2.256-37.7 ± 2.288
SecondaryAdjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 1-2 Over Time for SE+ Participants

1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Mean · Joints count
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 1-2 Over Time for SE+ Participants
Joints countAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 29: Total Tender Joint Count-9.1 ± 0.580-8.6 ± 0.580
Day 29: Total Swollen Joint Count-6.2 ± 0.422-6.7 ± 0.422
Day 57: Total Tender Joint Count-11.9 ± 0.608-11.6 ± 0.621
Day 57: Total Swollen Joint Count-8.6 ± 0.378-8.8 ± 0.386
Day 85: Total Tender Joint Count-13.5 ± 0.608-12.7 ± 0.618
Day 85: Total Swollen Joint Count-9.5 ± 0.352-9.4 ± 0.358
Day 113: Total Tender Joint Count-14.5 ± 0.516-13.8 ± 0.526
Day 113: Total Swollen Joint Count-10.1 ± 0.321-9.8 ± 0.326
Day 141: Total Tender Joint Count-14.8 ± 0.499-13.9 ± 0.506
Day 141: Total Swollen Joint Count-10.4 ± 0.321-9.8 ± 0.325
Day 169: Total Tender Joint Count-14.7 ± 0.580-13.8 ± 0.583
Day 169: Total Swollen Joint Count-10.2 ± 0.397-9.7 ± 0.399
SecondaryAdjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 6 Over Time for SE+ Participants

6) Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI). For the eight disability categories (Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities), there is an aids or devices variables to record the type of assistance. If aids or devices and/or assistance from another person are checked for a category, the score is set to 2 (much difficulty), if the original score is 0 (no difficulty) or 1 (some difficulty). HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered (increasing scores for the 8 disability categories questionnaire indicate increasing level of difficulty with 0 being the lowest score "without any difficulty" and 3 being the highest score "unable to do". Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Mean · score on a scale
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 6 Over Time for SE+ Participants
score on a scaleAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 29: Disability Index-0.4 ± 0.047-0.5 ± 0.047
Day 57: Disability Index-0.6 ± 0.049-0.6 ± 0.050
Day 85: Disability Index-0.8 ± 0.050-0.7 ± 0.051
Day 113: Disability Index-0.8 ± 0.047-0.7 ± 0.048
Day 141: Disability Index-0.9 ± 0.046-0.8 ± 0.046
Day 169: Disability Index-0.9 ± 0.049-0.8 ± 0.050
SecondaryAdjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 7 Over Time for SE+ Participants

1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Mean · mg/L
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 7 Over Time for SE+ Participants
mg/LAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 29: C Reactive Protein (mg/L)-1.4 ± 1.986-8.1 ± 1.995
Day 57: C Reactive Protein (mg/L)-6.1 ± 0.818-7.4 ± 0.845
Day 85: C Reactive Protein (mg/L)-6.7 ± 0.745-8.6 ± 0.759
Day 113: C Reactive Protein (mg/L)-7.5 ± 0.701-7.3 ± 0.713
Day 141: C Reactive Protein (mg/L)-7.9 ± 0.724-7.6 ± 0.733
Day 169: C Reactive Protein (mg/L)-6.6 ± 1.083-5.4 ± 1.098
SecondaryAdjusted Mean Change From Baseline in Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein (DAS28-CRP) Over Time for All Participants

DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. Remission was defined as DAS28-CRP \< 2.6. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Mean · score on a scale
Adjusted Mean Change From Baseline in Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein (DAS28-CRP) Over Time for All Participants
score on a scaleAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 29-1.2 ± 0.084-1.5 ± 0.084
Day 57-1.9 ± 0.089-2.1 ± 0.089
Day 85-2.2 ± 0.091-2.4 ± 0.091
Day 113-2.6 ± 0.084-2.6 ± 0.084
Day 141-2.7 ± 0.085-2.5 ± 0.085
Day 169-2.6 ± 0.094-2.6 ± 0.093
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.0099 · Adjusted mean difference: 0.3 · 95% CI 0.1 to 0.5
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.1519 · Adjusted mean difference: 0.2 · 95% CI -0.1 to 0.4
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.2505 · Adjusted mean difference: 0.1 · 95% CI -0.1 to 0.4
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.5248 · Adjusted mean difference: -0.1 · 95% CI -0.3 to 0.2
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.1778 · Adjusted mean difference: -0.0 · 95% CI -0.3 to 0.2
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.8510 · Adjusted mean difference: -0.0 · 95% CI -0.3 to 0.2
SecondaryAdjusted Mean Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time for All Participants

CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI remission was defined as =\<2.8. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Mean · score on a scale
Adjusted Mean Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time for All Participants
score on a scaleAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 29-14.6 ± 0.818-15.9 ± 0.823
Day 57-20.9 ± 0.786-21.6 ± 0.784
Day 85-23.5 ± 0.763-23.5 ± 0.769
Day 113-26.6 ± 0.644-25.4 ± 0.646
Day 141-27.1 ± 0.647-25.2 ± 0.631
Day 169-26.7 ± 0.763-25.4 ± 0.749
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.2319 · Adjusted mean difference: 1.3 · 95% CI -0.9 to 3.5
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.5572 · Adjusted mean difference: 0.6 · 95% CI -1.5 to 2.7
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.9366 · Adjusted mean difference: 0.1 · 95% CI -2.0 to 2.1
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.1508 · Adjusted mean difference: -1.2 · 95% CI -3.5 to 1.0
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.0303 · Adjusted mean difference: -1.9 · 95% CI -3.6 to -0.2
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.2333 · Adjusted mean difference: -1.2 · 95% CI -3.3 to 0.8
SecondaryAdjusted Mean Change From Baseline in Simple Disease Activity Index (SDAI) Over Time for All Participants

SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. Remission was defined as SDAI =\< 3.3. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Mean · Score on a scale
Adjusted Mean Change From Baseline in Simple Disease Activity Index (SDAI) Over Time for All Participants
Score on a scaleAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 29-14.7 ± 0.843-16.6 ± 0.849
Day 57-21.5 ± 0.788-22.1 ± 0.789
Day 85-24.0 ± 0.769-24.2 ± 0.775
Day 113-27.2 ± 0.648-26.0 ± 0.649
Day 141-27.7 ± 0.661-25.8 ± 0.647
Day 169-27.3 ± 0.787-26.0 ± 0.771
Statistical analysis
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.0938 · Adjusted mean difference: 1.9 · 95% CI -0.3 to 4.2
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.6053 · Adjusted mean difference: 0.6 · 95% CI -1.6 to 2.7
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.8570 · Adjusted mean difference: 0.2 · 95% CI -1.9 to 2.3
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.1592 · Adjusted mean difference: -1.2 · 95% CI -3.0 to 0.5
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.0319 · Adjusted mean difference: -1.9 · 95% CI -3.7 to -0.2
  • Abatacept vs Adalimumab, Then Abatacept (OLE Period) · longitudinal · p = 0.2059 · Adjusted mean difference: -1.3 · 95% CI -3.4 to 0.7
SecondaryAdjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 3-5 Over Time for All Participants

1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Mean · score on a scale
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 3-5 Over Time for All Participants
score on a scaleAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 29: Participants Global Assess Disease Activity (mm)-19.4 ± 1.865-20.6 ± 1.868
Day 29: Physician Global Assess Disease Activity (mm)-24.4 ± 1.613-27.7 ± 1.612
Day 29: Participants Assessment of Pain (mm)-19.2 ± 1.872-22.7 ± 1.863
Day 57: Participants Global Assess Disease Activity (mm)-27.3 ± 1.888-28.3 ± 1.893
Day 57: Physician Global Assess Disease Activity (mm)-35.7 ± 1.583-36.7 ± 1.579
Day 57: Participants Assessment of Pain (mm)-25.9 ± 1.957-28.7 ± 1.954
Day 85: Participants Global Assess Disease Activity (mm)-32.8 ± 1.874-32.8 ± 1.884
Day 85: Physician Global Assess Disease Activity (mm)-40.1 ± 1.459-41.2 ± 1.459
Day 85: Participants Assessment of Pain (mm)-32.1 ± 1.939-33.7 ± 1.923
Day 113: Participants Global Assess Disease Activity (mm)-37.7 ± 1.787-34.8 ± 1.780
Day 113: Physician Global Assess Disease Activity (mm)-46.8 ± 1.216-44.9 ± 1.218
Day 113: Participants Assessment of Pain (mm)-36.6 ± 1.883-33.9 ± 1.871
Day 141: Participants Global Assess Disease Activity (mm)-38.4 ± 1.866-34.1 ± 1.856
Day 141: Physician Global Assess Disease Activity (mm)-48.5 ± 1.258-45.2 ± 1.221
Day 141: Participants Assessment of Pain (mm)-38.7 ± 1.858-35.4 ± 1.830
Day 169: Participants Global Assess Disease Activity (mm)-39.1 ± 1.842-36.6 ± 1.827
Day 169: Physician Global Assess Disease Activity (mm)-47.7 ± 1.320-46.2 ± 1.296
Day 169: Participants Assessment of Pain (mm)-39.5 ± 1.895-37.0 ± 1.864
SecondaryAdjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 1-2 Over Time for All Participants

1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Mean · Joints count
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 1-2 Over Time for All Participants
Joints countAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 29: Total Tender Joint Count-8.1 ± 0.529-8.2 ± 0.527
Day 29: Total Swollen Joint Count-6.1 ± 0.374-6.6 ± 0.372
Day 57: Total Tender Joint Count-11.3 ± 0.549-11.1 ± 0.545
Day 57: Total Swollen Joint Count-8.7 ± 0.322-8.7 ± 0.319
Day 85: Total Tender Joint Count-12.7 ± 0.507-12.4 ± 0.506
Day 85: Total Swollen Joint Count-9.3 ± 0.289-9.4 ± 0.289
Day 113: Total Tender Joint Count-14.4 ± 0.411-13.9 ± 0.410
Day 113: Total Swollen Joint Count-10.1 ± 0.255-9.8 ± 0.254
Day 141: Total Tender Joint Count-14.8 ± 0.417-13.8 ± 0.414
Day 141: Total Swollen Joint Count-10.6 ± 0.259-9.9 ± 0.257
Day 169: Total Tender Joint Count-14.5 ± 0.474-13.8 ± 0.468
Day 169: Total Swollen Joint Count-10.2 ± 0.311-9.8 ± 0.307
SecondaryAdjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 6 Over Time for All Participants

6) Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI). For the eight disability categories (Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities), there is an aids or devices variables to record the type of assistance. If aids or devices and/or assistance from another person are checked for a category, the score is set to 2 (much difficulty), if the original score is 0 (no difficulty) or 1 (some difficulty). HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered (increasing scores for the 8 disability categories questionnaire indicate increasing level of difficulty with 0 being the lowest score "without any difficulty" and 3 being the highest score "unable to do". Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Mean · score on a scale
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 6 Over Time for All Participants
score on a scaleAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 29: Disability Index-0.4 ± 0.040-0.5 ± 0.040
Day 57: Disability Index-0.6 ± 0.042-0.6 ± 0.042
Day 85: Disability Index-0.7 ± 0.043-0.6 ± 0.043
Day 113: Disability Index-0.7 ± 0.041-0.7 ± 0.041
Day 141: Disability Index-0.8 ± 0.040-0.7 ± 0.040
Day 169: Disability Index-0.8 ± 0.042-0.8 ± 0.042
SecondaryAdjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 7 Over Time for All Participants

1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.

Time frame:
Baseline, day 29, 57, 85, 113, 141, 169
Reported as:
Mean · mg/L
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 7 Over Time for All Participants
mg/LAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 29: C Reactive Protein (mg/L)-1.4 ± 1.520-6.8 ± 1.514
Day 57: C Reactive Protein (mg/L)-5.7 ± 0.635-6.4 ± 0.635
Day 85: C Reactive Protein (mg/L)-5.4 ± 0.719-6.6 ± 0.717
Day 113: C Reactive Protein (mg/L)-5.7 ± 0.704-5.8 ± 0.702
Day 141: C Reactive Protein (mg/L)-5.9 ± 0.778-5.5 ± 0.774
Day 169: C Reactive Protein (mg/L)-6.2 ± 0.912-5.0 ± 0.900
SecondaryAdjusted Mean Change From Baseline in 36-item Short Form Survey (SF-36) Over Time for SE+ Participants

SF-36 is a generic 36-item questionnaire measuring health-related quality of life, which covers 8 health dimensions within 2 components. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100, with a higher score indicating better quality of life. The 8 subscales will be scored using norm-based methods that have standardized the T-scores to a mean of 50 and a standard deviation of 10 in the general population.

Time frame:
Up to week 24
Reported as:
Mean · T-score
Adjusted Mean Change From Baseline in 36-item Short Form Survey (SF-36) Over Time for SE+ Participants
T-scoreAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 169: Physical Functioning9.2 ± 0.8139.8 ± 0.817
Day 169: Role-Physical9.1 ± 0.8098.9 ± 0.805
Day 169: Bodily Pain14.2 ± 0.86312.0 ± 0.859
Day 169: General Health8.1 ± 0.7796.5 ± 0.783
Day 169: Vitality10.0 ± 0.8788.4 ± 0.874
Day 169: Social Functioning9.6 ± 0.8289.4 ± 0.824
Day 169: Role-Emotional9.0 ± 0.9219.1 ± 0.917
Day 169: Mental Health8.9 ± 0.7997.1 ± 0.795
Day 169: Physical Component Summary10.2 ± 0.7389.6 ± 0.735
Day 169: Mental Component Summary8.4 ± 0.8187.3 ± 0.814
SecondaryAdjusted Mean Change From Baseline in SF-36 Over Time for All Participants

SF-36 is a generic 36-item questionnaire measuring health-related quality of life, which covers 8 health dimensions within 2 components. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100, with a higher score indicating better quality of life. The 8 subscales will be scored using norm-based methods that have standardized the T-scores to a mean of 50 and a standard deviation of 10 in the general population.

Time frame:
Up to week 24
Reported as:
Mean · T-score
Adjusted Mean Change From Baseline in SF-36 Over Time for All Participants
T-scoreAbataceptAdalimumab, Then Abatacept (OLE Period)
Day 169: Physical Functioning8.9 ± 0.7069.4 ± 0.697
Day 169: Role-Physical8.6 ± 0.6818.7 ± 0.669
Day 169: Bodily Pain13.5 ± 0.71911.7 ± 0.706
Day 169: General Health7.9 ± 0.6526.7 ± 0.644
Day 169: Vitality9.4 ± 0.7408.8 ± 0.725
Day 169: Social Functioning8.9 ± 0.7019.8 ± 0.690
Day 169: Role-Emotional8.4 ± 0.7738.8 ± 0.759
Day 169: Mental Health8.0 ± 0.7127.6 ± 0.700
Day 169: Physical Component Summary9.9 ± 0.6199.2 ± 0.608
Day 169: Mental Component Summary7.6 ± 0.7187.7 ± 0.705
SecondaryAdjusted Mean Change From Baseline in 36-item Short Form Survey (SF-36) at Week 104 for SE+ Participants

The SF-36 v2.0, which covers 8 health dimensions within 2 components. The physical component summary (PCS) of the SF-36 consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. The 2 summary scores (PCS and MCS) will be calculated by taking a weighted linear combination of the 8 individual subscales. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Up to week 24

Results for this outcome have not been posted.

SecondaryAdjusted Mean Change From Baseline in 36-item Short Form Survey (SF-36) at Week 104 for All Participants

The SF-36 v2.0, which covers 8 health dimensions within 2 components. The physical component summary (PCS) of the SF-36 consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. The 2 summary scores (PCS and MCS) will be calculated by taking a weighted linear combination of the 8 individual subscales. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.

Time frame:
Up to week 24

Results for this outcome have not been posted.

Adverse events

Collected over All-cause mortality was collected from first dose till death (Up to 20 months). Serious adverse events and non-serious adverse events were collected from first dose until 56 days after last dose of study therapy (Up to approximately 9 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept Only0/169 (0%)4/169 (2.4%)34/169 (20.1%)
Adalimumab, Then Abatacept (OLE Period)0/169 (0%)6/169 (3.6%)41/169 (24.3%)
Most frequent serious events
Most frequent serious events
EventAbatacept OnlyAdalimumab, Then Abatacept (OLE Period)
Atypical pneumoniaInfections and infestations0/1691/169
Pilonidal diseaseInfections and infestations0/1691/169
Open fractureInjury, poisoning and procedural complications1/1690/169
ArthritisMusculoskeletal and connective tissue disorders0/1691/169
Foot deformityMusculoskeletal and connective tissue disorders1/1690/169
Neuroendocrine tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1690/169
Migraine with auraNervous system disorders0/1691/169
Renal colicRenal and urinary disorders1/1690/169
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1691/169
HaematomaVascular disorders0/1691/169
Most frequent other events
Most frequent other events
EventAbatacept OnlyAdalimumab, Then Abatacept (OLE Period)
COVID-19Infections and infestations20/16923/169
NasopharyngitisInfections and infestations11/16910/169
Upper respiratory tract infectionInfections and infestations4/16910/169

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AbataceptAdalimumab, Then Abatacept (OLE Period)Total
Mean49.3 ± 13.7147.4 ± 13.4348.4 ± 13.59
Sex: Female, Male
Sex: Female, Male(Participants)AbataceptAdalimumab, Then Abatacept (OLE Period)Total
Female130138268
Male393170
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AbataceptAdalimumab, Then Abatacept (OLE Period)Total
American Indian or Alaska Native9918
Asian172340
Native Hawaiian or Other Pacific Islander000
Black or African American415
White122113235
More than one race000
Unknown or Not Reported172340
08

Study locations

75 sites
  • Local Institution - 0036
    Fullerton, California 92835, United States
  • Local Institution - 0086
    Los Alamitos, California 90720, United States
  • Local Institution - 0041
    Aurora, Colorado 80045, United States
  • Local Institution - 0058
    Cumberland, Maryland 21502, United States
  • Local Institution - 0038
    Hagerstown, Maryland 21740, United States
  • Local Institution - 0084
    Eagan, Minnesota 55121, United States
  • Local Institution - 0040
    Freehold, New Jersey 07728, United States
  • NYU Langone Ambulatory Care Brooklyn Heights
    Brooklyn, New York 11201, United States
  • Local Institution - 0082
    Wilmington, North Carolina 28401, United States
  • Local Institution - 0127
    Portland, Oregon 97239, United States
  • Local Institution - 0031
    Duncansville, Pennsylvania 16635, United States
  • Local Institution - 0034
    Jackson, Tennessee 38305, United States
  • Local Institution - 0044
    Dallas, Texas 75231, United States
  • Local Institution - 0119
    Milwaukee, Wisconsin 53217, United States
  • Local Institution - 0012
    Caba, Buenos Aires C1015ABO, Argentina
  • Local Institution - 0016
    Quilmes, Buenos Aires 1878, Argentina
  • Local Institution - 0014
    San Isidro, Buenos Aires 1642, Argentina
  • Local Institution - 0057
    San Miguel de Tucumán, Tucuman T4000, Argentina
  • Local Institution - 0022
    Buenos Aires, 1428, Argentina
  • Local Institution - 0023
    Buenos Aires, 1428, Argentina
  • Local Institution - 0015
    Buenos Aires, 1431, Argentina
  • Local Institution - 0099
    Cordoba, 0, Argentina
  • Local Institution - 0072
    Botany, New South Wales 2019, Australia
  • Local Institution - 0062
    Paramatta, New South Wales 2150, Australia
  • Local Institution - 0063
    Maroochydore, Queensland 4558, Australia
  • Local Institution - 0102
    Woodville South, South Australia 5011, Australia
  • Local Institution - 0064
    Camberwell, Victoria 3124, Australia
  • Local Institution - 0065
    Geelong, Victoria 3220, Australia
  • Local Institution - 0105
    Ivanhoe, Victoria 3079, Australia
  • Local Institution - 0028
    Brno, 638 00, Czechia
  • Local Institution - 0025
    Praha 2, 12850, Czechia
  • Local Institution - 0001
    Montpellier, 34295, France
  • Local Institution - 0047
    Rouen, 76031, France
  • Local Institution - 0035
    Strasbourg, 67098, France
  • Local Institution - 0002
    Toulouse, 31059, France
  • Local Institution - 0059
    Berlin, 10117, Germany
  • Local Institution - 0055
    Bonn, 53127, Germany
  • Local Institution - 0091
    Freiburg, 79106, Germany
  • Local Institution - 0053
    Hamburg, 20095, Germany
  • Local Institution - 0056
    Planegg, 82152, Germany
  • Local Institution - 0083
    Catania, 95121, Italy
  • Local Institution - 0077
    Pavia, 27100, Italy
  • Local Institution - 0078
    Perugia, 06156, Italy
  • Local Institution - 0100
    Roma, 00168, Italy
  • Local Institution - 0093
    Nagoya, Aichi 457-8511, Japan
  • Local Institution - 0079
    Kitakyushu, Fukuoka 807-8556, Japan
  • Local Institution - 0110
    Sapporo, Hokkaido 0608648, Japan
  • Local Institution - 0046
    Sendai-shi, Miyagi 980-8574, Japan
  • Local Institution - 0112
    Sasebo, Nagasaki 857-1195, Japan
  • Local Institution - 0090
    Kawagoe, Saitama 350-8550, Japan
  • Local Institution - 0089
    Tokyo, 104-8560, Japan
  • Local Institution - 0010
    Tokyo, 1600035, Japan
  • Local Institution - 0006
    Cdmx, Distrito Federal 11850, Mexico
  • Local Institution - 0008
    Mexico City, Distrito Federal 14080, Mexico
  • Local Institution - 0017
    Guadalajara, Jalisco 44650, Mexico
  • Local Institution - 0117
    Guadalajara, Jalisco 44650, Mexico
  • Local Institution - 0118
    San Luis Potosí, SAN LUIS Potosi 78200, Mexico
  • Local Institution - 0005
    Mérida, Yucatán 97070, Mexico
  • Local Institution - 0009
    Chihuahua, 31000, Mexico
  • Local Institution - 0020
    Torun, Kujawsko-pomorskie 87-100, Poland
  • Local Institution - 0124
    Bydgoszcz, 85-168, Poland
  • Local Institution - 0019
    Elblag, 82-300, Poland
  • Local Institution - 0004
    A Coruña, 15006, Spain
  • Local Institution - 0003
    Madrid, 28046, Spain
  • Local Institution - 0085
    Santander, 39008, Spain
  • Local Institution - 0049
    Basel, 4031, Switzerland
  • Local Institution - 0052
    St. Gallen, 9007, Switzerland
  • Local Institution - 0098
    Kaohsiung Niao Sung Dist, 83301, Taiwan
  • Local Institution - 0104
    New Taipei City, 220, Taiwan
  • Local Institution - 0095
    Taichung City, 402, Taiwan
  • Local Institution - 0096
    Taichung, 40447, Taiwan
  • Local Institution - 0120
    Tainan, 704, Taiwan
  • Local Institution - 0111
    Cannock, Staffordshire WS11 5XY, United Kingdom
  • Local Institution - 0060
    Hull, HU3 2JZ, United Kingdom
  • Local Institution - 0114
    London, SE1 9RT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jun 2023, 20 months.

Results were first posted in Oct 2024, 1 year 4 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 20 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2021
First posted
Jun 2, 2021
StartActual
Sep 15, 2021
Primary completionActual
Jun 14, 2023
CompletionEst.
Sep 1, 2027
Results first posted
Oct 15, 2024
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04909801
Responsible party
Sponsor
First posted
Jun 2, 2021
Start date
Sep 15, 2021
Primary completion
Jun 14, 2023
Completion
Sep 1, 2027 (estimated)
Results posted
Oct 15, 2024
Last update
Feb 19, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abatacept · Methotrexate

Start the discussion